Abstract Bone metastases occur in 20–40% of patients with lung cancer. Recent studies
demonstrate a direct antiproliferative effect of 3rd generation bisphosphonates (BPs) on lung
tumors, which may influence the survival. Therefore, we examined the clinical impact of
zoledronic acid (ZOL; Zometa®), a 3rd generation BP, with a focus on the survival, time to
progression and pain effect in lung cancer patients with bone metastases. Lung cancer
patients (n= 144, Stage IV) with evidence of metastasis bone scan were included. Eighty …

e15096 Background: Bone metastases occur in almost 40% of patients with bladder cancer.
M-VAC chemotherapy to bone metastasis has been done and median survival time is 10
months.(Bajorin, JCO 17, 3173, 1999). Recent studies demonstrate a direct antiproliferative
effect of 3rd generation bisphosphonates (BPs) on bladder tumors, which may influence the
survival. Therefore, we examined the clinical impact of zoledronic acid (ZOL; Zometa), a 3rd
generation BP, with a focus on the survival, time to progression and pain effect in bladder …